Cryoablation is no longer offered at our hospital, and likely won't be offered in the near future.
A Prospective Randomized Pilot Trial of Cryoablation (CA) Versus Radio Frequency Ablation (RFA) for the Management of Small Renal Masses
Sponsor study identifier
interventional
0
1 country
1
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2015
Actual (reported)Study Completion
March 2015
Actual (reported)The purpose of this study is to verify the oncological efficacy and safety of cryoablation and radiofrequency ablation for the treatment of small renal tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 16, 2009
Actual (reported)June 17, 2009
Actual (reported)March 2010
Date type not reportedThis date has not been verified as actual or estimated.
March 2015
Actual (reported)March 2015
Actual (reported)Treatment failure rate.
Baseline, Weeks 6, 12, 24, 36, 48
Renal function - GFR of less than 60 ml per min per 1.73 m2. Serum creatinine and creatinine clearance.
Baseline, Weeks 6, 12, 24, 36 and 48
Average percentage decrease in tumor size.
Baseline, Weeks 6, 12, 24, 36 and 48
Intra and post-operative complications rates.
Weeks 6, 12, 24, 36 and 48
Quality of life data.
Baseline, Weeks 6, 12, 24, 36 and 48
Radiofrequency ablation
Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
McMaster Institute of Urology - St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6, Canada
Anil Kapoor, MD
McMaster Institute of Urology, McMaster University
0 participants (actual enrollment reported by the registry).
First Submitted
June 16, 2009
First Posted
June 17, 2009
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 2015
Actual (reported)Study Completion
March 2015
Actual (reported)Last Updated
July 27, 2016
Record last verified: 2016-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: